Scientific Advances in Lung Cancer 2015

[1]  P. Stephens,et al.  Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Yufeng Shen,et al.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Ladanyi,et al.  Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. , 2016, The oncologist.

[4]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[5]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[6]  M. Ladanyi,et al.  Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Giaccone,et al.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? , 2022 .

[8]  D. Costa,et al.  Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches , 2016, Therapeutic advances in respiratory disease.

[9]  A. Nicholson,et al.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  R. Govindan,et al.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Elizabeth H. Payne,et al.  The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. , 2016, American journal of respiratory and critical care medicine.

[12]  K. Kerr,et al.  Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. , 2016, Archives of pathology & laboratory medicine.

[13]  S. Ou,et al.  A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib. , 2016, Lung cancer.

[14]  M. Socinski,et al.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. , 2016, The Lancet. Oncology.

[15]  F. Hirsch,et al.  Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? , 2016, Archives of pathology & laboratory medicine.

[16]  G. Getz,et al.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.

[17]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  L. Bubendorf,et al.  Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients , 2016, Journal of Thoracic Oncology.

[19]  M. Mino‐Kenudson,et al.  Tumor islands and spread through air spaces: Distinct patterns of invasion in lung adenocarcinoma , 2016, Pathology international.

[20]  M. Ladanyi,et al.  A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer , 2015, Clinical Cancer Research.

[21]  K. O'Byrne,et al.  LBA2_PRAfatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7) , 2015 .

[22]  Hisao Asamura,et al.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Manish B. Patel,et al.  Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  K. Jöckel,et al.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Crinò,et al.  Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. , 2015, Lung cancer.

[26]  K. Cummings,et al.  Identifying Targeted Strategies to Improve Smoking Cessation Support for Cancer Patients , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  P. Parikh,et al.  Prospective Phase 2 Clinical Trial of Radiation Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Lung Cancer: An Institutional Trial , 2015 .

[28]  Fei Li,et al.  Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[31]  Bin Li,et al.  Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients , 2015, Oncotarget.

[32]  Mary W Redman,et al.  The Master Protocol Concept. , 2015, Seminars in oncology.

[33]  Mary W Redman,et al.  Lung-MAP--framework, overview, and design principles. , 2015, Chinese clinical oncology.

[34]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  R. Mirimanoff,et al.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial , 2015, The Lancet.

[36]  David R Jones,et al.  Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Austin,et al.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  R. Collins,et al.  Emerging Tobacco-Related Cancer Risks in China: A Nationwide, Prospective Study of 0.5 Million Adults , 2015, Cancer.

[39]  Chun-Ming Tsai,et al.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Asthana,et al.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer , 2015, Nature Medicine.

[41]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[42]  Andrew D Althouse,et al.  Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections , 2015, Modern Pathology.

[43]  M. Piccart,et al.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  C. Dooms,et al.  2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  J. Samet,et al.  An Official American Thoracic Society Research Statement: Current Understanding and Future Research Needs in Tobacco Control and Treatment. , 2015, American journal of respiratory and critical care medicine.

[46]  G. Scagliotti,et al.  Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Shibing Deng,et al.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. , 2015, Cancer cell.

[48]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[49]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[50]  M. Ferguson,et al.  Video-Assisted versus Open Lobectomy in Patients with Compromised Lung Function: A Literature Review and Meta-Analysis , 2015, PloS one.

[51]  Y. Ichinose,et al.  Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[53]  A. Scarsbrook,et al.  Risk of malignancy in pulmonary nodules: A validation study of four prediction models. , 2015, Lung cancer.

[54]  Ming-Sound Tsao,et al.  Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[55]  Ashutosh Kumar Singh,et al.  Tobacco Cessation May Improve Lung Cancer Patient Survival , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[56]  A. Sokolenko,et al.  Novel ALK fusion partners in lung cancer. , 2015, Cancer letters.

[57]  C. Henschke,et al.  CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds. , 2015, Radiology.

[58]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Prokop,et al.  British Thoracic Society guidelines for the investigation and management of pulmonary nodules: accredited by NICE , 2015, Thorax.

[60]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[61]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Stephens,et al.  Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. , 2015, Lung cancer.

[63]  Peter Balter,et al.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. , 2015, The Lancet. Oncology.

[64]  Yixin Zeng,et al.  BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[65]  A. Warth,et al.  Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma , 2015, The American journal of surgical pathology.

[66]  Qingqing Zhu,et al.  Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. , 2015, Translational lung cancer research.

[67]  H. Groen,et al.  Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). , 2015 .

[68]  A. Shaw,et al.  Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. , 2015 .

[69]  K. Steele,et al.  Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. , 2015 .

[70]  H. Wakelee,et al.  Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). , 2015 .

[71]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[72]  R. Rosell,et al.  Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699). , 2015 .

[73]  Keunchil Park,et al.  Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). , 2015 .

[74]  N. Schultz,et al.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. , 2015, Cancer discovery.

[75]  F. Song,et al.  Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials , 2015, Thorax.

[76]  S. Ou,et al.  I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. , 2015, Lung cancer.

[77]  David R. Jones,et al.  Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[78]  Gwénaël Le Teuff,et al.  Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  G. Warren,et al.  Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions. , 2015, Translational lung cancer research.

[80]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[81]  M. Sonobe,et al.  Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. , 2015, The Annals of thoracic surgery.

[82]  J. Mazières,et al.  Targeting the immune system to treat lung cancer: rationale and clinical experience , 2015, Therapeutic advances in respiratory disease.

[83]  Roman K. Thomas,et al.  Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Colin Jacobs,et al.  Predictive Accuracy of the PanCan Lung Cancer Risk Prediction Model -External Validation based on CT from the Danish Lung Cancer Screening Trial , 2015, European Radiology.

[85]  M. McTigue,et al.  PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations , 2015, Proceedings of the National Academy of Sciences.

[86]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[87]  J. Engelman,et al.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib , 2015, Clinical Cancer Research.

[88]  W. Eberhardt.  Concurrent chemoradiotherapy in stage III non-small-cell lung cancer: what is the best regimen? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Dong-Wan Kim,et al.  Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[90]  David Wholley,et al.  Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.

[91]  S. Ou,et al.  Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. , 2015, The oncologist.

[92]  P. Brastianos,et al.  Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[93]  M. Ladanyi,et al.  Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches , 2015, Clinical Cancer Research.

[94]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[95]  Timothy R. Church,et al.  Evaluation of the Lung Cancer Risks at Which to Screen Ever- and Never-Smokers: Screening Rules Applied to the PLCO and NLST Cohorts , 2014, PLoS medicine.

[96]  Yang Zhang,et al.  The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma , 2014, Scientific Reports.

[97]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[98]  A. Iafrate,et al.  Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.

[99]  Arash Naeim,et al.  Cost-effectiveness of CT screening in the National Lung Screening Trial. , 2014, The New England journal of medicine.

[100]  J. Ross,et al.  RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[101]  Hisao Asamura,et al.  The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[102]  M. Ladanyi,et al.  Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[103]  G. Warren,et al.  The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. , 2014, The Lancet. Oncology.

[104]  M. Sonobe,et al.  Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. , 2014, European journal of cancer.

[105]  H. Sakamoto,et al.  Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer , 2014, Molecular Cancer Therapeutics.

[106]  G. Veronesi,et al.  Positron emission tomography in the diagnostic work-up of screening-detected lung nodules , 2014, European Respiratory Journal.

[107]  Heidi Roberts,et al.  Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[108]  N. Altorki,et al.  1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[109]  H. Asamura.  Role of limited sublobar resection for early-stage lung cancer: steady progress. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  T. Chou,et al.  Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  J. O’Shaughnessy,et al.  BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. , 2014, Lung cancer.

[112]  S. Shiono,et al.  The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. , 2014, The Annals of thoracic surgery.

[113]  Massimo Bellomi,et al.  Diagnostic Performance of Low-Dose Computed Tomography Screening for Lung Cancer over Five Years , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[114]  C. Gridelli,et al.  Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[116]  Stephen Lam,et al.  Screening for lung cancer using low dose computed tomography , 2014, BMJ : British Medical Journal.

[117]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[118]  A. Iafrate,et al.  Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). , 2014 .

[119]  N. Segal,et al.  A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. , 2014 .

[120]  J. Soria,et al.  Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  L. Ellis,et al.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Akihiko Yoshizawa,et al.  Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease , 2014, The American journal of surgical pathology.

[123]  Martin Vingron,et al.  Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids , 2014, Nature Communications.

[124]  V. Moyer.  Screening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2014, Annals of Internal Medicine.

[125]  Ho Yun Lee,et al.  Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome. , 2014, The Journal of thoracic and cardiovascular surgery.

[126]  G. Scagliotti,et al.  Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC , 2014 .

[127]  Sharyl J. Nass,et al.  Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis , 2014 .

[128]  Yong Soo Choi,et al.  Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  T. Chou,et al.  Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma , 2013, Annals of surgery.

[130]  A. Abernethy,et al.  Delivering high-quality and affordable care throughout the cancer care continuum. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  Z Guo,et al.  Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[132]  S. Peters,et al.  Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. , 2013, Lung cancer.

[133]  G. Getz,et al.  A Genomics-Based Classification of Human Lung Tumors , 2013, Science Translational Medicine.

[134]  C. Toon,et al.  The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma , 2013, Pathology.

[135]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[136]  S. Lam,et al.  Probability of cancer in pulmonary nodules detected on first screening CT. , 2013, The New England journal of medicine.

[137]  Q. Tan,et al.  Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis?: A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS Classification , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[138]  H. Asamura,et al.  The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. , 2013, Lung cancer.

[139]  Prasad S Adusumilli,et al.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. , 2013, Journal of the National Cancer Institute.

[140]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[141]  C. Berg,et al.  Targeting of low-dose CT screening according to the risk of lung-cancer death. , 2013, The New England journal of medicine.

[142]  H. D. de Koning,et al.  Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial , 2013, European Respiratory Journal.

[143]  Olivier Michielin,et al.  Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Masahiko Kusumoto,et al.  Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. , 2013, The Journal of thoracic and cardiovascular surgery.

[145]  David C. Smith,et al.  Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[147]  Lu Wang,et al.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[148]  G. Giaccone,et al.  Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. , 2013 .

[149]  C. Rudin,et al.  Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. , 2013 .

[150]  P. Jänne,et al.  MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). , 2013 .

[151]  Keunchil Park,et al.  Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. , 2013 .

[152]  P. V. Van Schil,et al.  Radical treatment of non-small cell lung cancer during the last 5 years. , 2013, European journal of cancer.

[153]  S. Aebi,et al.  A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[154]  Jie Gu,et al.  Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients—A single institution retrospective study of 292 lung adenocarcinoma , 2012, Journal of surgical oncology.

[155]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[157]  Timothy R Church,et al.  Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.

[158]  Maristela L Onozato,et al.  Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis , 2013, The American journal of surgical pathology.

[159]  Michael J Thun,et al.  50-year trends in smoking-related mortality in the United States. , 2013, The New England journal of medicine.

[160]  A. Yoshizawa,et al.  Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[161]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  Hideaki Mitsui,et al.  Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases , 2012, Pathology international.

[163]  S. Wang,et al.  Clinical controlled comparison between lobectomy and segmental resection for patients over 70 years of age with clinical stage I non-small cell lung cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[164]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[165]  S. Aebi,et al.  A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[166]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[167]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[168]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[169]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[170]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[171]  G. Scagliotti,et al.  Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. , 2012, Clinical lung cancer.

[172]  Ugo Pastorino,et al.  Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial , 2012, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[173]  Michael Thomas,et al.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  C. Hoggart,et al.  A risk model for lung cancer incidence. , 2012, Cancer prevention research.

[175]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[176]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[177]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.

[178]  A. Dirksen,et al.  CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT , 2012, Thorax.

[179]  S. Digumarthy,et al.  Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[180]  H. D. de Koning,et al.  NELSON lung cancer screening study , 2011, Cancer imaging : the official publication of the International Cancer Imaging Society.

[181]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[182]  P. V. Van Schil,et al.  Current surgical treatment of non-small-cell lung cancer , 2011, Expert review of anticancer therapy.

[183]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  Zoe Wainer,et al.  Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[185]  L. Sequist,et al.  Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  V. Rusch,et al.  Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification , 2011, European Respiratory Journal.

[187]  P. Prorok,et al.  Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. , 2011, Journal of the National Cancer Institute.

[188]  A. Bernard,et al.  Surgical treatment of lung cancer in the octogenarians: results of a nationwide audit. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[189]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  H. Wakelee,et al.  Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[192]  Jeffrey W. Clark,et al.  Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[193]  G. Pelosi,et al.  Screening-Detected Lung Cancers: Is Systematic Nodal Dissection Always Essential? , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[194]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[195]  A. Dirksen,et al.  Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning , 2010, Thorax.

[196]  H. Ji,et al.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[198]  M. Tsuboi,et al.  A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). , 2010, Japanese journal of clinical oncology.

[199]  Harry J de Koning,et al.  Management of lung nodules detected by volume CT scanning. , 2009, The New England journal of medicine.

[200]  Armando Santoro,et al.  A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. , 2009, American journal of respiratory and critical care medicine.

[201]  A. Marchetti,et al.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  Y. Yatabe,et al.  Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[203]  Y. Ohe,et al.  EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[204]  P. V. Van Schil,et al.  Surgery for oligometastatic disease in non-small-cell lung cancer , 2008, Expert review of anticancer therapy.

[205]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  M. Ladanyi,et al.  Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[207]  M. Gaub,et al.  MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[208]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[209]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[210]  J. Habbema,et al.  Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON) , 2007, International journal of cancer.

[211]  D. Xu,et al.  Nodule management protocol of the NELSON randomised lung cancer screening trial. , 2006, Lung cancer.

[212]  O. Miettinen,et al.  Survival of Patients with Stage I Lung Cancer Detected on CT Screening , 2008 .

[213]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[214]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[215]  J. Luketich,et al.  Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. , 2006, The Annals of thoracic surgery.

[216]  E. Stoelben,et al.  [Multimodal treatment of non small cell lung cancer]. , 2006, Zentralblatt fur Chirurgie.

[217]  R. Rami-Porta,et al.  Complete resection in lung cancer surgery: proposed definition. , 2005, Lung cancer.

[218]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[219]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[220]  M. Kris,et al.  A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. , 2002, Lung cancer.

[221]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[222]  D. Sidransky,et al.  Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.

[223]  T. Nakajima,et al.  Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance , 1996, Japanese journal of cancer research : Gann.

[224]  P. Lee.  Lung cancer and passive smoking. , 1991, British Journal of Cancer.

[225]  Jeffrey W. Clark,et al.  MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer , 2017 .

[226]  Ashutosh Kumar Singh,et al.  Primary Study Endpoint Analysis for NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-Small Cell Lung Cancer (NSCLC) , 2016 .

[227]  David R Jones,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[228]  S. Ou,et al.  ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. , 2016, Lung cancer.

[229]  M. Tammemägi.  Application of risk prediction models to lung cancer screening: a review. , 2015, Journal of thoracic imaging.

[230]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[231]  T. Kohno,et al.  Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[232]  B. Lushniak,et al.  The Health consequences of smoking—50 years of progress : a report of the Surgeon General , 2014 .

[233]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[234]  Dawei Yang.  Estimating overdiagnosis in low-dose computed tomography screening for lung cancer : a cohort study , 2013 .

[235]  Matthijs Oudkerk,et al.  International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[236]  M. L. R. D. Christenson,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[237]  D. Lynch,et al.  The National Lung Screening Trial: overview and study design. , 2011, Radiology.

[238]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[239]  D. Solís.  US Food and Drug Administration , 2010 .